TXG 10x Genomics, Inc.
FY2025 10-K
10x Genomics, Inc. (TXG) filed its fiscal year 2025 10-K annual report with the SEC on Feb 13, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
- • New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided text
- • No segment performance data included
Risk Factors
- • Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
- • Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
Financial SummaryXBRL
Revenue
$643M
Net Income
-$44M
Gross Margin
69.1%
Operating Margin
-9.5%
Net Margin
-6.8%
ROE
-5.5%
Total Assets
$1.0B
EPS (Diluted)
$-0.35
Operating Cash Flow
$136M
Source: XBRL data from 10x Genomics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on 10x Genomics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.